Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 577

1.

MDMA, methamphetamine and their combination: possible lessons for party drug users from recent preclinical research.

Clemens KJ, McGregor IS, Hunt GE, Cornish JL.

Drug Alcohol Rev. 2007 Jan;26(1):9-15. Review.

PMID:
17364831
2.

Repeated weekly exposure to MDMA, methamphetamine or their combination: long-term behavioural and neurochemical effects in rats.

Clemens KJ, Cornish JL, Hunt GE, McGregor IS.

Drug Alcohol Depend. 2007 Jan 12;86(2-3):183-90. Epub 2006 Aug 1.

PMID:
16884865
3.

MDMA ('Ecstasy') and methamphetamine combined: order of administration influences hyperthermic and long-term adverse effects in female rats.

Clemens KJ, Cornish JL, Li KM, Hunt GE, McGregor IS.

Neuropharmacology. 2005 Aug;49(2):195-207.

PMID:
15993443
4.

The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview.

Gouzoulis-Mayfrank E, Daumann J.

J Psychopharmacol. 2006 Mar;20(2):188-93. Review.

PMID:
16510477
5.

Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.

Thomasius R, Zapletalova P, Petersen K, Buchert R, Andresen B, Wartberg L, Nebeling B, Schmoldt A.

J Psychopharmacol. 2006 Mar;20(2):211-25. Review.

PMID:
16510479
7.

MDMA ("ecstasy"), methamphetamine and their combination: long-term changes in social interaction and neurochemistry in the rat.

Clemens KJ, Van Nieuwenhuyzen PS, Li KM, Cornish JL, Hunt GE, McGregor IS.

Psychopharmacology (Berl). 2004 May;173(3-4):318-25. Epub 2004 Mar 17.

PMID:
15029472
8.

Intravenous methamphetamine self-administration in rats: effects of intravenous or intraperitoneal MDMA co-administration.

Clemens KJ, Cornish JL, Hunt GE, McGregor IS.

Pharmacol Biochem Behav. 2006 Oct;85(2):454-63. Epub 2006 Nov 15.

PMID:
17112571
9.

Ecstasy: are animal data consistent between species and can they translate to humans?

Easton N, Marsden CA.

J Psychopharmacol. 2006 Mar;20(2):194-210. Review.

PMID:
16510478
10.

The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").

Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI.

Pharmacol Rev. 2003 Sep;55(3):463-508. Epub 2003 Jul 17. Review.

11.

Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity.

Hansen JP, Riddle EL, Sandoval V, Brown JM, Gibb JW, Hanson GR, Fleckenstein AE.

J Pharmacol Exp Ther. 2002 Mar;300(3):1093-100.

12.

Methamphetamine and MDMA (ecstasy) neurotoxicity: 'of mice and men'.

Itzhak Y, Achat-Mendes C.

IUBMB Life. 2004 May;56(5):249-55. Review.

14.

Involvement of nicotinic receptors in methamphetamine- and MDMA-induced neurotoxicity: pharmacological implications.

Escubedo E, Camarasa J, Chipana C, García-Ratés S, Pubill D.

Int Rev Neurobiol. 2009;88:121-66. doi: 10.1016/S0074-7742(09)88006-9. Review.

PMID:
19897077
15.

Changes in leptin, ghrelin, growth hormone and neuropeptide-Y after an acute model of MDMA and methamphetamine exposure in rats.

Kobeissy FH, Jeung JA, Warren MW, Geier JE, Gold MS.

Addict Biol. 2008 Mar;13(1):15-25. Epub 2007 Oct 2.

PMID:
17910739
16.

Methylenedioxymethamphetamine (MDMA, Ecstasy) neurotoxicity: cellular and molecular mechanisms.

Lyles J, Cadet JL.

Brain Res Brain Res Rev. 2003 May;42(2):155-68. Review.

PMID:
12738056
17.
18.

Cognitive function and mood in MDMA/THC users, THC users and non-drug using controls.

Lamers CT, Bechara A, Rizzo M, Ramaekers JG.

J Psychopharmacol. 2006 Mar;20(2):302-11.

PMID:
16510488
19.
20.

Supplemental Content

Support Center